Delphine Davan 🌎 (@delphinedavan) header
Delphine Davan 🌎 (@delphinedavan) profile picture

Scientist, biz woman, mother, pet lover, outdoor addict & other adventures in 3 countries 🇫🇷~🇺🇸~🇨🇦

Québec, Canada
Joined June 2009
Photo by Delphine Davan 🌎 (@delphinedavan)Photo by Delphine Davan 🌎 (@delphinedavan)Photo by Delphine Davan 🌎 (@delphinedavan)Photo by Delphine Davan 🌎 (@delphinedavan)Photo by Delphine Davan 🌎 (@delphinedavan)Photo by Delphine Davan 🌎 (@delphinedavan)Photo by Delphine Davan 🌎 (@delphinedavan)Photo by Delphine Davan 🌎 (@delphinedavan)Photo by Delphine Davan 🌎 (@delphinedavan)Photo by Delphine Davan 🌎 (@delphinedavan)
Delphine Davan 🌎 retweeted
Last June, our lead asset (MDNA55 or bizaxofusp) was featured on the cover page of #NeuroOncologyJournal. In this Phase 2b study in patients with rec. #glioblastoma, MDNA55 has doubled the mOS compared to SOC. All details in this #publication: ncbi.nlm.nih.gov/pmc/article…
1
4
1
10
3,509
Delphine Davan 🌎 retweeted
#TBT to our clinical update on the ABILITY study in patients with advanced solid tumors. MDNA11 demonstrated an excellent #SafetyProfile across all cohorts and early signs of response: #PartialResponse in a patient with pancreatic cancer. See more here: bit.ly/46gZFP1
3
1
9
2,314
Delphine Davan 🌎 retweeted
This Monday, we will present the preclinical results of our dual-functioning MDNA223 BiSKIT at the @AACR Special Conference in #CancerResearch: Tumor Immunology and #Immunotherapy. Learn about our MDNA BiSKIT program here: bit.ly/468DydM
4
6
282
In Ph1 trial, @Medicenna1 MDNA11 #monotherapy was well tolerated across all cohorts and has shown promising therapeutic activity in patients who have progressed on multiple prior anti-#cancer therapies including a patient with a particularly aggressive form of #PancreaticCancer.
Single-agent activity and durable #tumor control: #MDNA11 shows tumor control in 37% of patients. #MDNA11 demonstrated partial response in a patient with a highly aggressive tumor type. For more updates, click the link ir.medicenna.com/news-releas…
3
127
Delphine Davan 🌎 retweeted
Single-agent activity and durable #tumor control: #MDNA11 shows tumor control in 37% of patients. #MDNA11 demonstrated partial response in a patient with a highly aggressive tumor type. For more updates, click the link ir.medicenna.com/news-releas…
3
1
8
357
Viens réseauter avec les professionnels de la #Communication et du #Marketing de la #CapitaleNationale ce jeudi soir en terrasse. Notre comité événement a commandé une belle température pour l'occasion ! lnkd.in/e3Tg7kBD
13
Mobilisation locale pour reprendre les installations de Medicago et faire de la @ville_de_quebec un pôle de recherche biopharmaceutique. #biotech #biopharma lnkd.in/eCzGnr_6
18
Jour 2 à EFFERVESCENCE MTL où je suis ravie de représenter l'Agence IMPAKT Scientifik Inc., une entreprise québécoise spécialisée dans la communication scientifique ! Venez me rencontrer pour en savoir plus.! lnkd.in/eyFS7krG
1
2
348
Création d’un pôle d’innovation dédié aux #SciencesDeLaVie et de la #SantéDurable sur les installations de Medicago à Québec! When life gives you lemons, make lemonade! #innovation Québec VITAE #VilleDeQuébec lnkd.in/eYQ7hGqT
28
Pensez-vous être suffisamment outillé pour gérer une crise lorsqu'elle se présentera ? Peut-on être trop préparé ? (demandez aux pompiers). RDV le 25 avril. lnkd.in/gMJHRZYA
11
When antigens are delivered the right way to the immune system, it generates a targeted response that leads to clinical benefit with limited adverse events. MVP-S is IMV's first DPX-enabled #cancervaccine and has shown durable clinical benefit in several…lnkd.in/e-3cei8S
27
Delphine Davan 🌎 retweeted
In June, we join @CancerResearch in celebrating 10 years of Cancer Immunotherapy Month! #Immunotherapy has the potential to bring targeted, long-lasting therapies to #cancer patients. Get involved with @CancerResearch here: https://teapawt.org/t.co/eVHHq87JvX #Immune2Cancer
1
3
8
Future RI governor @helena_foulkes talking about aligning strategy on corporate purpose. She's a cancer survivor and was head of IR when @cvspharmacy removed tobacco from their stores. 👏🏻 #niri2022
Peptide therapeutics have many advantages. #Immunotherapy #wvc2022